Myriad Genetics, Inc. (MYGN): Price and Financial Metrics
Myriad Genetics, Inc. (MYGN)
Today's Latest Price: $13.99 USD
Updated Oct 28 10:06am
Add MYGN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
MYGN Stock Summary
- MYGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.29 -- higher than merely 14.39% of US-listed equities with positive expected earnings growth.
- In terms of twelve month growth in earnings before interest and taxes, Myriad Genetics Inc is reporting a growth rate of -1,840.98%; that's higher than only 0.93% of US stocks.
- As for revenue growth, note that MYGN's revenue has grown -24.97% over the past 12 months; that beats the revenue growth of only 11.58% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Myriad Genetics Inc are OFIX, MMSI, ENZ, RFL, and IOSP.
- Visit MYGN's SEC page to see the company's official filings. To visit the company's web site, go to myriad.com.
MYGN Stock Price Chart Interactive Chart >
MYGN Price/Volume Stats
| Current price | $13.99 | 52-week high | $35.29 |
| Prev. close | $14.35 | 52-week low | $9.24 |
| Day low | $13.91 | Volume | 28,858 |
| Day high | $14.35 | Avg. volume | 999,673 |
| 50-day MA | $13.33 | Dividend yield | N/A |
| 200-day MA | $15.16 | Market Cap | 1.05B |
Myriad Genetics, Inc. (MYGN) Company Bio
Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.
MYGN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $13.99 | $2.19 | -85% |
Below please find a table outlining a discounted cash flow forecast for MYGN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Myriad Genetics Inc ranked in the 14th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 84.67%. The most interesting components of our discounted cash flow analysis for Myriad Genetics Inc ended up being:
- Its compound free cash flow growth rate, as measured over the past 5.53 years, is -0.1% -- higher than merely 14.8% of stocks in our DCF forecasting set.
- Myriad Genetics Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -19.67. This coverage rate is greater than that of just 5.59% of stocks we're observing for the purpose of forecasting via discounted cash flows.
- The weighted average cost of capital for the company is 11. This value is greater than 83.24% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -85% |
| 1% | -85% |
| 2% | -85% |
| 3% | -85% |
| 4% | -84% |
| 5% | -84% |
Want more companies with a valuation profile/forecast similar to that of Myriad Genetics Inc? See IDXX, LMNX, BSX, ELAN, and NUVA.
Loading social stream, please wait...